<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043312</url>
  </required_header>
  <id_info>
    <org_study_id>833561</org_study_id>
    <nct_id>NCT04043312</nct_id>
  </id_info>
  <brief_title>Magnetic Stimulation to Treat VT Storm</brief_title>
  <acronym>STAR-VT</acronym>
  <official_title>A Randomized Controled Trial of Transcutaneous Magnetic Stimulation of the Stellate Ganglion to Treat Ventricular Tachycardia Storm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventricular Tachycardia storm is a medical emergency characterized by three or more episodes
      of ventricular arrhythmia within 24 hours and associated with a significantly increased
      mortality and massive health resource utilization. Several therapies are utilized including
      sympathetic blockade (through deep sedation and beta blockers), antiarrhythmic drugs,
      implantable cardioverter defibrillator (ICD) reprograming where applicable, and catheter
      ablation. Despite standard intervention, mortality rates remain high and additional
      therapeutic options are actively being investigated.

      The overall objective of this proposal is to investigate whether transcutaneous magnetic
      stimulation designed to inhibit the left stellate ganglion can be used in this population.
      This is a single-center, randomized, sham-controlled trial to assess the efficacy of
      transcutaneous magnetic stimulation of the left stellate ganglion to treat patients with
      ventricular tachycardia storm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular Tachycardia - Incidence of ventricular tachycardia on inpatient telemetry monitoring</measure>
    <time_frame>24-hours following completion of the protocol</time_frame>
    <description>Incidence of ventricular tachycardia on inpatient telemetry monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardioversion - Incidence of ICD or external defibrillation following stimulation on device interrogation or telemetry</measure>
    <time_frame>48-hours following completion of the protocol</time_frame>
    <description>Incidence of ICD or external defibrillation following stimulation on device interrogation or telemetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ICD or pacemaker lead impedances</measure>
    <time_frame>Immediately following completion of the protocol</time_frame>
    <description>Change in lead impedance (unit: Ohms) on device interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ICD or pacemaker lead thresholds</measure>
    <time_frame>Immediately following completion of the protocol</time_frame>
    <description>Change in lead thresholds (unit: mV) on device interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ICD or pacemaker lead sensitivities</measure>
    <time_frame>Immediately following completion of the protocol</time_frame>
    <description>Change in lead sensitivity (unit: mA) on device interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local effect from stimulation - Incidence of local skin irritation or patient reported local discomfort on visual analog scale (1-10)</measure>
    <time_frame>Immediately following completion of the protocol</time_frame>
    <description>Incidence of local skin irritation or patient reported local discomfort on visual analog scale (1-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiarrhythmic drugs used post stimulation - Incidence of antiarrhythmic drug use post stimulation per inpatient medical record</measure>
    <time_frame>72 hours following completion of the protocol</time_frame>
    <description>Incidence of antiarrhythmic drug use post stimulation per inpatient medical record</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive one hour of sham stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive one hour of active magnetic stimulation to the left stellate ganglion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim SuperRapid</intervention_name>
    <description>Transcutaneous magnetic stimulation targeting the left stellate ganglion.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim SuperRapid</intervention_name>
    <description>Sham transcutaneous magnetic stimulation.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 3 episodes of VT in 24 hours

        Exclusion Criteria:

          -  Pregnancy

          -  Implanted ventricular assist device

          -  Metal implanted in head or neck (except the mouth)

          -  Implanted medication pumps

          -  Cochlear implant

          -  Implanted brain stimulator

          -  Ocular implant

          -  History of malignancy in region of stimulation (neck)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy Markman, MD</last_name>
    <phone>2675930103</phone>
    <email>timothy.markman@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Markman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

